Key Takeaways
- •TB-500, also referred to as Thymosin Beta 4, is a naturally occurring peptide found in elevated concentrations within blood platelets, wound fluid, and various other tissues throughout the body.
- •Numerous preclinical investigations have identified a range of biologic activities for TB-500 (Thymosin Beta 4, Tβ4), with effects that appear to be tissue-specific.
- •Recent clinical research conducted by RegeneRx Biopharmaceuticals was presented at the Second International Symposium on Thymosins in Health and Disease, held in Catania, Italy.
Introduction to TB-500 (Thymosin Beta 4)
TB-500, also referred to as Thymosin Beta 4, is a naturally occurring peptide found in elevated concentrations within blood platelets, wound fluid, and various other tissues throughout the body. Unlike growth factors, TB-500 functions primarily as a major actin-regulating peptide. Research indicates that Thymosin Beta 4 plays a critical role in the protection, regeneration, and remodeling of injured or damaged tissues. Studies have further demonstrated that the gene encoding TB-500 is among the first to be upregulated following the onset of a wound, suggesting its involvement in early reparative processes.
Preclinical Biological Activities
Numerous preclinical investigations have identified a range of biologic activities for TB-500 (Thymosin Beta 4, Tβ4), with effects that appear to be tissue-specific. These studies have highlighted the peptide’s capacity to modulate cellular responses across different tissue types, though the precise mechanisms continue to be explored in experimental models.
Research on Myocardial Applications
Recent clinical research conducted by RegeneRx Biopharmaceuticals was presented at the Second International Symposium on Thymosins in Health and Disease, held in Catania, Italy. The findings detailed the biological properties supporting both near-term and long-term clinical applications of TB-500. Particular emphasis was placed on the development of TB-500 for the systemic treatment of patients experiencing ST-elevation myocardial infarction (STEMI) , administered in combination with percutaneous coronary intervention—the current standard of care for this common form of heart attack in most Western countries. According to investigators, the objective of TB-500 peptide research in this context is to prevent or repair ongoing damage to cardiac tissue following a heart attack, particularly when tissue surrounding the injury site remains vulnerable.
Phase I Safety Study Outcomes
The most recent results from a Phase I safety study of TB-500, titled “A Randomized, Double-blind, Placebo-controlled, Dose-response Phase I Study of the Safety and Tolerability of the Intravenous Administration of TB-500 (Thymosin Beta 4) Peptide and its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers,” were reported. The study concluded that there were no dose-limiting or serious adverse events throughout the dosing period. Synthetic TB-500 (Thymosin Beta 4, Tβ4), administered intravenously at doses up to 1260 mg and for durations of up to 14 days, appeared to be well tolerated, with a low incidence of adverse events and no evidence of serious adverse events, according to Dr. Dennis Ruff, vice president and medical director of ICON.
Reviewed by the Volta Peptides Research Team